Research programme: TGF-beta antisense oligonucleotides - Isarna Therapeutics

Drug Profile

Research programme: TGF-beta antisense oligonucleotides - Isarna Therapeutics

Alternative Names: ASPH-0047; ASPH-1047; ASPH-1106; ISTH0047

Latest Information Update: 13 Jan 2015

Price : $50

At a glance

  • Originator Isarna Therapeutics
  • Class Antisense oligonucleotides
  • Mechanism of Action Transforming growth factor beta1 inhibitors; Transforming growth factor beta2 inhibitors; Transforming growth factor beta3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Fibrosis; Glaucoma

Most Recent Events

  • 09 Jan 2015 Preclinical trials in Fibrosis in Germany (Parenteral)
  • 09 Jan 2015 Preclinical trials in Glaucoma in Germany before January 2015 (Parenteral)
  • 09 Jan 2015 Isarna files a clinical trial application with the National Organization for Medicines in Germany for Glaucoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top